The BRMP is interested in the extramural clinical evaluation of monoclonal antibodies, and intends to turn its attentionto the area of immunoconjugates. A number of Phase I clinical trials have been carried out using several monoclonal antibodies in human malignancies. The BRMP intends to support a limited number of Phase I/II trials utilizing T101 and another monoclonal antibody against a solid tumor, conjugated with either radioisotopes, doxorubicin, or vindesine.
| Lindgren, C G; Thompson, J A; Higuchi, C M et al. (1993) Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4. J Immunother Emphasis Tumor Immunol 14:322-8 |
| Thompson, J A; Shulman, K L; Benyunes, M C et al. (1992) Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 10:960-8 |
| Treisman, J; Higuchi, C M; Thompson, J A et al. (1990) Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients. Cancer Res 50:1160-4 |
| Higuchi, C M; Thompson, J A; Lindgren, C G et al. (1989) Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. Cancer Res 49:6487-92 |
